IceCure Medical to Engage Investors at Exclusive 2025 Maxim Growth Summit

IceCure Medical Ltd. (NASDAQ: ICCM), a trailblazing Israeli medical device company dedicated to pioneering minimally invasive cryoablation solutions for tumor treatment, has officially announced its participation in the prestigious 2025 Maxim Growth Summit.

This significant event will see IceCure’s Chief Executive Officer, Eyal Shamir, hosting an array of focused one-on-one meetings with institutional investors.

Scheduled for Wednesday, October 8, 2025, these sessions are set to highlight the company's innovative advancements and strategic vision in the medical technology landscape.

Founded in 2006, IceCure Medical has established itself as a leader in developing and marketing the groundbreaking ProSense® Cryoablation System.

This state-of-the-art, minimally invasive technology leverages liquid nitrogen to induce cryoablation, also known as cryotherapy, offering a powerful alternative to traditional surgical tumor removal. The ProSense® system precisely targets and destroys both benign and malignant tumors by freezing them, minimizing patient discomfort and recovery time.

The ProSense® Cryoablation System boasts impressive credentials, holding CE clearance, FDA clearance, and approvals in numerous other countries.

Its versatility allows for the effective treatment of tumors located in vital organs such as the breast, kidney, bone, lung, and liver, providing a less intrusive option for patients seeking advanced therapeutic solutions. IceCure Medical continues to innovate, committed to improving patient outcomes through cutting-edge medical devices.

For more detailed information on their transformative technology and mission, interested parties are encouraged to visit www.icecure-medical.com.